 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12345678910111213...3940» |
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: SEMA-AP: Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care (clinicaltrials.gov) - Aug 25, 2023
P2/3, N=28, Active, not recruiting, Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Recruiting --> Active, not recruiting
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Using Gastric Ultrasound At The Bedside In Patients Taking GLP1 Agonists. A Case Report of Retained Solid Gastric Contents in a Patient Undergoing Anesthesia. (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_4978;
She had recently started semaglutide (Ozempic) and her last solid food intake occurred 18 hours prior...Upon further investigation, a gastric ultrasound revealed the antrum filled with solid contents, and the case was delayed. This highlights the effect of GLP-1 agonists on bowel motility and gastric emptying, and the utility of bedside gastric ultrasound to quickly assess for potential gastric contents.
- | Mounjaro (tirzepatide) / Eli Lilly
Journal: Tirzepatide in Hispanic/Latino Patients with Type 2 Diabetes: A Subgroup Analysis of the SURPASS program. (Pubmed Central) - Aug 21, 2023
Tirzepatide was generally well tolerated in both subgroups. Efficacy and safety trends were comparable between subgroups and with the overall trial populations.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Daily Highlights by the Argentine Society of Cardiology: HOT LINE 1 (STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity) (Global Stage; Online) - Aug 21, 2023 - Abstract #ESC2023ESC_6840;
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
New P3 trial, Combination therapy: REDEFINE 6: A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (clinicaltrials.gov) - Aug 18, 2023
P3, N=300, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: Semaglutide Use in Elderly Obese Patients (clinicaltrials.gov) - Aug 15, 2023
P4, N=16, Recruiting, Sponsor: State University of New York at Buffalo
Efficacy and safety trends were comparable between subgroups and with the overall trial populations. Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Nov 2023
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, HEOR, Real-world evidence, Real-world: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial (clinicaltrials.gov) - Aug 15, 2023
P4, N=1278, Completed, Sponsor: Novo Nordisk A/S
Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Nov 2023 Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events. (Pubmed Central) - Aug 14, 2023
Active, not recruiting --> Completed Semaglutide treatment in eligible US adults may substantially reduce obesity prevalence and CVD events, which may dramatically impact associated healthcare costs.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight (clinicaltrials.gov) - Aug 9, 2023
P2, N=240, Active, not recruiting, Sponsor: Novo Nordisk A/S
Semaglutide treatment in eligible US adults may substantially reduce obesity prevalence and CVD events, which may dramatically impact associated healthcare costs. Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, ecnoglutide SC (XW003) / Sciwind Biosci
Journal: Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. (Pubmed Central) - Aug 7, 2023
P1
Ecnoglutide showed a favorable potency, pharmacokinetic, and tolerability profile, as well as a simplified manufacturing process. These results support the continued development of ecnoglutide for the treatment of type 2 diabetes and obesity.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
In the USA, where prescription medication adverts are allowed, @novonordisk has removed its TV commercials due to an inability to meet the surging demand for Wegovy https://t.co/wLbp8neik3 (Twitter) - Aug 3, 2023
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system. (Pubmed Central) - Aug 2, 2023
Our study suggests that once-weekly GLP-1 RA may have a potential protective effect on cardiovascular events in patients with T2DM combined with CAD, possibly through the renin-angiotensin system. However, further research is needed to confirm these findings and determine cause and effect.
- | Mounjaro (tirzepatide) / Eli Lilly
Journal, Patient reported outcomes: Patient-Reported Outcomes in People with Type (Pubmed Central) - Aug 1, 2023
P3
However, further research is needed to confirm these findings and determine cause and effect. Overall, tirzepatide produced significant health and weight-related QoL improvements versus comparators in the five SURPASS studies.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Retrospective data, Review, Journal: Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. (Pubmed Central) - Jul 31, 2023
The risk of serious, severe, moderate, and mild adverse events did not significantly differ between the two treatments. In conclusion, the administration of once-weekly Semaglutide exhibited a substantial reduction in HbA1c, average systolic blood pressure (SBP), mean diastolic blood pressure (DBP), body weight, waist circumference, body mass index (BMI), and a rise in pulse rate, as opposed to the once-daily administration of Sitagliptin.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Exploring Patterns and Implications of Semaglutide Misuse: A Descriptive Study (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1632;
Analysis of 4,266 patients revealed a female majority (73% vs. 27% male) among Semaglutide users. The majority were white (69%), with 18% Black or African American, and 3% Asian.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Acute Pancreatitis Due to Semaglutide: Another Medication to Worry About! (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_522;
Current medications were metformin 500 mg daily, zolpidem 50 mg daily, lisinopril 10 mg daily, atorvastatin 500 mg twice daily by mouth along with 0.5 mg subcutaneous semaglutide once weekly (started two months prior to presentation)...Figure: FIG-1A: Computed tomography (CT) scan of the abdomen and pelvis with contrast showed no pancreatic pathology. Figure 1B: Magnetic resonance cholangiopancreatography (MRCP) showing a normal caliber common bile duct, pancreatic duct, and a remnant cystic duct status post cholecystectomy.
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Clinical: agree, its implemented in our practice. Every patient is offered saxenda or ozempic as first line treatment. I remember the euphoria around semaglutide. It‘s already quiet. We need to combine all modalities. Personalised obesity treatment. (Twitter) - Jul 29, 2023
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Clinical, Real-world evidence, Surgery, Real-world: Actually is what we see after saxenda/ozempic euphoria. 2/3 of users do not respond and most seek help by metabolic surgery. Most of which did refuse surgery in the first place. Real world experience🔁🔁we call it jojo effect here in switzerland (Twitter) - Jul 29, 2023
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
HEOR, Surgery, Cost effectiveness, Bariatric surgery: The most durable and costeffective ozempic comes from within after bariatric surgery. Endogenous golden standard⬆️⬆️⬆️ (Twitter) - Jul 29, 2023
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial primary completion date: STEP HFpEF DM: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (clinicaltrials.gov) - Jul 28, 2023
P3, N=610, Recruiting, Sponsor: Novo Nordisk A/S
Figure 1B: Magnetic resonance cholangiopancreatography (MRCP) showing a normal caliber common bile duct, pancreatic duct, and a remnant cystic duct status post cholecystectomy. Trial primary completion date: Jun 2023 --> Oct 2023
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Surgery: I will keep telling anyone and everyone that will and even won't listen. I had a 55 lb regain after a 130 lb weight loss in 2019. My doctor wanted me to try wegovy and none of the drugs or surgery was covered. It's infuriating. These are tools to help the obese lose weight. (Twitter) - Jul 27, 2023
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Retrospective data, Review: Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials. (Pubmed Central) - Jul 21, 2023
Clinicians can choose suitable treatment schemes based on diverse individual situations. https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=337099, identifier PROSPERO (CRD42022337099).
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: STEP 10: Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes (clinicaltrials.gov) - Jul 21, 2023
P3, N=181, Completed, Sponsor: Novo Nordisk A/S
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=337099, identifier PROSPERO (CRD42022337099). Active, not recruiting --> Completed
- PN127. Breaking News: GLP-1 agonists, SGLT2 inhibitors, CNS Stimulants - Perioperative Implications (South: 205/206) - Jul 20, 2023 - Abstract #ASA2023ASA_664;
Examples of GLP-1 RAs include exenatide (twice-daily and extended-release once-weekly), lixisenatide (once-daily), liraglutide (once-daily), dulaglutide (once-weekly), semaglutide (once-weekly), and oral semaglutide (once-daily)...During this panel, our experts will dissect the multifaceted impact of these medications on anesthetic care and patient safety, offering a comprehensive overview of their perioperative implications. Join us as we navigate the forefront of medical innovation and its intricate connection to the world of anesthesia.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jul 20, 2023
P3, N=478, Not yet recruiting, Sponsor: Qilu Pharmaceutical Co., Ltd.
- ||| Firsocostat (GS-0976) / Gilead, cilofexor/firsocostat (GS-9674/GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
Enrollment closed: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jul 20, 2023
P2, N=457, Active, not recruiting, Sponsor: Gilead Sciences
Join us as we navigate the forefront of medical innovation and its intricate connection to the world of anesthesia. Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal, HEOR, Patient reported outcomes: Effect of once-weekly subcutaneous semaglutide 2.4 (Pubmed Central) - Jul 18, 2023
Recruiting --> Active, not recruiting Benefits favouring semaglutide 2.4
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Semaglutide Once Weekly Helps Adolescents Lose Weight, but 4% Developed Acute Cholelithiasis. (Pubmed Central) - Jul 17, 2023
Benefits favouring semaglutide 2.4 No abstract available
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Warning Issued for 'Nature's Ozempic' Supplement https://t.co/7TbcEerf60 via @medscape (Twitter) - Jul 17, 2023
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
I've been on Ozempic for 2 years. Lost 25 pounds and my A1C has dropped nearly a full point. No suicidal thoughts here; just glad to be healthier. (Twitter) - Jul 17, 2023
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Clinical, European regulatory: The European Medicines Agency is broadening its investigation into a class of weight loss and diabetes drugs after patients reported thoughts of self-harm and suicide after taking Ozempic and Saxenda. @celinegounder joined @CBSNews to discuss. More: https://t.co/4bUXgk0tYx (Twitter) - Jul 17, 2023
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Does Ozempic Cause Hair Loss? https://t.co/6s6SBVKYgE via @medscape (Twitter) - Jul 16, 2023
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Ant updates on when Wegovy will be available? (Twitter) - Jul 15, 2023
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Why do you talk about ozempic so much?? #ozempic #mounjaro #semaglutide @EliLillyandCo @novonordiskus (Twitter) - Jul 14, 2023
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@novonordisk any update on the Wegovy shortage? I was on month 3 and can’t get my dosages. (Twitter) - Jul 13, 2023
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) (clinicaltrials.gov) - Jul 13, 2023
P3, N=568, Recruiting, Sponsor: Novo Nordisk A/S
No abstract available Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Nov 2024
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: STEP Young: A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight (clinicaltrials.gov) - Jul 13, 2023
P3, N=210, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Nov 2024 Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Feasibility of Semaglutide in Advanced Lung Disease (clinicaltrials.gov) - Jul 12, 2023
P1/2, N=8, Not yet recruiting, Sponsor: University of Pennsylvania
Not yet recruiting --> Recruiting Trial completion date: Feb 2024 --> Jun 2024 | Initiation date: May 2023 --> Sep 2023 | Trial primary completion date: Feb 2024 --> Jun 2024
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: STRIDE: A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (clinicaltrials.gov) - Jul 12, 2023
P3, N=800, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Feb 2024 --> Jun 2024 | Initiation date: May 2023 --> Sep 2023 | Trial primary completion date: Feb 2024 --> Jun 2024 Recruiting --> Active, not recruiting
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: FOCUS: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (clinicaltrials.gov) - Jul 12, 2023
P3, N=1500, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Clinical, Retrospective data, Journal: Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis. (Pubmed Central) - Jul 11, 2023
Regimens of GLP-1RAs had differential glycemic control. The efficacy and safety of Semaglutide 2.0mg in comprehensively lowering blood sugar showed the best performance.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. (Pubmed Central) - Jul 10, 2023
The efficacy and safety of Semaglutide 2.0mg in comprehensively lowering blood sugar showed the best performance. An exposure-response model has been established that quantitatively describes the relationship between systemic semaglutide exposure and weight loss and predicts weight-loss trajectories for people with overweight or obesity who are receiving semaglutide doses up to 2.4?mg once weekly.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P2 trial, Combination therapy: HALLMARK: The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (clinicaltrials.gov) - Jul 10, 2023
P2, N=20, Not yet recruiting, Sponsor: University Health Network, Toronto
- ||| metformin / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk
I use Ozempic with Metformin for diabetes and I have lost weight. When you say diet and exercise you have lost me. Losing your appetite is the most important part of losing weight. If diet and exercise worked we would certainly know by now! (Twitter) - Jul 8, 2023
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@novonordisk why is it @Walgreens can't get wegovy after a month, but @redmountainwl is able to get ahold it it per their ads, and radio announcement from DJ? (Twitter) - Jul 7, 2023
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity (Amsterdam; Online) - Jul 7, 2023 - Abstract #ESC2023ESC_5990;
- |||| efinopegdutide (HM12525A) / Merck (MSD)
Enrollment open: A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) (clinicaltrials.gov) - Jul 7, 2023
P2b, N=300, Recruiting, Sponsor: Merck Sharp & Dohme LLC
An exposure-response model has been established that quantitatively describes the relationship between systemic semaglutide exposure and weight loss and predicts weight-loss trajectories for people with overweight or obesity who are receiving semaglutide doses up to 2.4?mg once weekly. Not yet recruiting --> Recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Enrollment change, Trial completion date: TRANSITION-T2D: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Jul 7, 2023
P4, N=60, Active, not recruiting, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=100 --> 60 | Trial completion date: Jun 2023 --> Nov 2023
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Safety profile of semaglutide in people aged 55 years and over: pooled data from the PIONEER, SUSTAIN and STEP phase 3 clinical programmes (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3849;
P3
Recruiting --> Active, not recruiting | N=100 --> 60 | Trial completion date: Jun 2023 --> Nov 2023 Safety data for participants ?55 years were pooled for: people with T2D receiving once-daily oral semaglutide 3, 7 or 14 mg versus comparator (active or placebo) for 26?78 weeks in PIONEER 1?5 and 7?10 (PIONEER pool, N=4186); people with T2D receiving once-weekly subcutaneous semaglutide 0.5 or 1 mg versus comparator (active or placebo) for 30?56 weeks in SUSTAIN 1?5 and SUSTAIN Japan (NCT02207374 and NCT02254291; SUSTAIN pool, N=2825); and people with overweight/obesity (with/without T2D) receiving once-weekly subcutaneous semaglutide 2.4 mg versus placebo for 68?104 weeks in STEP 1
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@novonordisk is Wegovy 2.4mg in shortage now? I can’t find it anywhere. (Twitter) - Jul 6, 2023